You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline and follow-up characteristics of HIV-infected women in the MTCT-Plus program (N = 290).

From: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire

At initiation of treatment  
Period at HAART initiation  
   Pregnant/non pregnant, n (%) 125/165 (43/57)
Exposed women to PMTCT  
   Exposed/no exposed, n (%) 153/137 (53/47)
Age, years, median [IQR] 29 [26-33]
   >29 years 137 (47)
Body mass index, Kg/m2 [IQR] 22.3 [20.1-25.3]
   >18.5 * 250 (86)
WHO clinical stage, n (%)  
   1 33 (11)
   2 127 (44)
   3 117 (40)
   4 13 (5)
CD4 counts, cells/mm3 [IQR] 186 [124-266]
   >250 88 (30)
Co-trimoxazole, n (%) 287 (99)
Haemoglobin level, g/l, median [IQR] 9.8 [9-11]
   ≤9.8 150 (52)
Neutrophil count, mm3, median [IQR] 2639 2639 [1911-3712]
   <1500 28 (10)
HAART regimen, n (%)  
   ZDV/3TC/NVP 265 (91)
   d4T/3TC/NVP 25 (9)
Alanine aminotransferase, UI, median [IQR] 15 [11-24]
   <31 IU/L* 240 (83)
Aspartate aminotransférase, UI, median [IQR] 24 [19-31]
   <32 IU/L* 235 (81)
Follow-up  
Cumulative, person-months 6388
Per patient, months, median [IQR] 25 [14-30]
Status on study termination  
   Dead, n (%) 16 (6)
   Lost to follow-up, n (%) 7 (2)
   Alive, n (%) 267 (92)
  1. HAART: Highly active antiretroviral therapy; PMTCT: prevention to mother-to-child transmission; WHO: World Health Organization; IQR: interquartile range; ZDV: zidovudine; 3TC: lamivudine; NVP: nevirapine; d4T: stavudine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; IU: International unity;
  2. * upper limit of normal